BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
Phase 3
Completed
- Conditions
- Moderate Depressive Episodes (Major Depression)
- Interventions
- Drug: Laif® 900, BAY98-7108Drug: Placebo
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 398
- Registration Number
- NCT04315597
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Phase 2
Completed
- Conditions
- Central Nervous System Pathology
- Interventions
- Drug: Gadoquatrane (BAY1747846)
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 57
- Registration Number
- NCT04307186
- Locations
- 🇧🇬
UMHAT Sveti Georgi, Plovdiv, Bulgaria
🇧🇬University Multiprofile Hosp. for Active Treat. Sveti Ivan, Sofia, Bulgaria
🇯🇵National Hospital Organization Kanmon Medical Center, Shimonoseki, Yamaguchi, Japan
Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed
Phase 4
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 221
- Registration Number
- NCT04307940
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Phase 2
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Other: BAY2433334 matching placebo
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1601
- Registration Number
- NCT04304534
- Locations
- 🇺🇸
Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
🇺🇸Logan Health Research, Kalispell, Montana, United States
🇳🇱Reinier de Graaf Gasthuis, Delft, Netherlands
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
Phase 2
Completed
- Conditions
- Acute Non-cardioembolic Ischemic Stroke
- Interventions
- Other: BAY2433334 matching placebo
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1808
- Registration Number
- NCT04304508
- Locations
- 🇺🇸
Guilford Neurologic Associates, Greensboro, North Carolina, United States
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺John Hunter Hospital, New Lambton, New South Wales, Australia
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
Completed
- Conditions
- Symptomatic Peripheral Artery Disease (Symptomatic PAD)Prevention of Atherothrombotic EventsCoronary Artery Disease (CAD)
- Interventions
- Drug: Acetylsalicylic acid(ASA)
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT04298567
- Locations
- 🇮🇳
Many locations, Multiple Locations, India
Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
Completed
- Conditions
- Non-Valvular Atrial Fibrillation
- Interventions
- Drug: VKAs
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25000
- Registration Number
- NCT04297072
- Locations
- 🇬🇧
Many locations, Multiple Locations, United Kingdom
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4301
- Registration Number
- NCT04281147
- Locations
- 🇨🇦
Multiple Locations, Multiple Locations, Canada
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
Phase 1
Completed
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT04275960
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Phase 1
Terminated
- Conditions
- Advanced Solid Tumors (Excluding Prostate Cancer)Ovarian Cancer
- Interventions
- Drug: Elimusertib (BAY1895344)
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04267939
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath